The olfactory ensheathing cell (OEC) has attracted with its rat counterpart, including expression of the low-affinity nerve growth factor receptor (L-NGFr) and much interest recently because of its potential for transplantation-based therapy of CNS disease. Rat similar growth factor requirements. Purified populations of human OECs obtained by selection with L-NGFr OECs are able to remyelinate demyelinated axons and support regeneration of damaged axons. Although OECs antibodies have extremely high viability in tissue culture, and are capable of remyelinating persistently can be grown readily from the rat, a macrosmatic species, it has been uncertain whether it would be demyelinated CNS axons following transplantation into experimentally induced demyelinating lesions in the rat similarly straightforward to obtain these cells from the human, a microsmatic species with a relatively poorly spinal cord. Thus, the human OEC represents an important new cell for the development of transplant developed olfactory system. In this study, we have identified a human OEC which shares many properties therapy of CNS diseases.
Introduction
Since the time of Cajal and Tello, much effort has been shown that rodent OECs are able to support axonal regrowth when transplanted into experimental models of spinal cord invested in attempting to provide a favourable environment for the regeneration of damaged CNS axons by transplanting injury (Li et al., 1997; Ramon-Cueto et al., 1998) and are also able to form myelin sheaths around regenerated or Schwann cells from the peripheral nervous system, where axon regeneration occurs with much greater efficiency. demyelinated axons, thereby permitting rapid saltatory conduction to occur (Franklin et al., 1996; Li et al., 1997 ; Another region of the nervous system where glia support axonal regrowth in adulthood is the olfactory system Imaizumi et al., 1998; Ramon-Cueto et al., 1998) . It has therefore been proposed that OECs may be suitable cells for (Graziadei et al., 1978; Graziadei and Graziadei, 1979) . Here, olfactory ensheathing cells (OECs) permit growing axons transplant-mediated repair of spinal cord trauma or nonrepairing foci of demyelination (such as may occur in chronic from neurons of the nasal cavity olfactory mucosa to re-enter the olfactory bulb of the brain and form synapses with multiple sclerosis). These data indicate that transplanted OECs have a repair repertoire that is similar to that of second-order neurons (Doucette, 1984) . Recent studies have Schwann cells, but may have advantages over these because Mannheim, Germany) were also assessed. For immunocytochemistry, OECs were plated on poly-L-lysine-coated of their ability to migrate and integrate within areas of astrocytosis that are characteristic of damaged CNS (Franklin coverslips . Primary antibodies were: the O4 antibody (gift of I. Sommer; 1 : 2 supernatant, IgM), anti-low-affinity nerve and Ramon-Cueto et al., 1998) .
A key issue regarding their therapeutic potential is whether growth factor receptor, p75 (L-NGFr) (Roche Diagnostics Ltd, Lewes, UK; 1 : 10, IgG1), anti-von Willebrand's factor cells similar to those obtained from rat exist in the human olfactory tissue and whether or not they can be grown in (VWF) (Dako Ltd, Cambridge, UK; 1 : 50, anti-rabbit), antivimentin (Boehringer Mannheim; 1 : 50, IgG1), anti-glial tissue culture. Although OECs can be grown readily from the rat (Ramon-Cueto and Nieto-Sampedro, 1992; Barnett fibrillary acidic protein (GFAP) (Sigma; 1 : 100, IgG1), antilaminin (Sigma; 1 : 20, anti-rabbit), anti-fibronectin (Gibco; , which has a highly developed olfactory system, it is by no means certain whether it is similarly straightforward 1 : 10, anti-rabbit), anti-olfactory marker proteins (gift of F. Margolis; 1 : 1000, anti-rabbit) and anti-S100 (Dako Ltd; to obtain these cells from humans, who have a relatively poorly developed olfactory system. In this study, we 1 : 100, anti-rabbit). Antibodies were visualized with the appropriate fluorochrome-conjugated secondary antibody. All demonstrate (i) that OECs, isolated from resected adult human olfactory bulb, can be grown in tissue culture with a secondary antibodies were purchased from Southern Biotechniques (Cambridge Bioscience, Cambridge, UK) or high viability, and (ii) that human OECs (hOECs) have the ability to form new myelin sheaths following transplantation Jackson Laboratories (Stratatec, Luton, Beds., UK). into areas of persistent demyelination in the adult rat CNS.
Purification of hOEC using L-NGFr and magnetic beads

Material and methods
For magnetic bead purification of OECs, 0.5 µg of mouse
Isolation and culturing of human OECs
anti-human L-NGFr was incubated with 10 7 Dynabeads Human olfactory bulbs were collected during surgery where (Dynal, Wirral, UK) and rotated for 30 min at room removal was a necessary part of normal surgical procedure.
temperature. Bead-bound antibody was collected with a Surgery was generally for tumour removal, although in no magnet, washed three times and resuspended in phosphatecase did the neoplastic process involve the olfactory bulbs. buffered saline 0.1% bovine serum albumin at 4 ϫ 10 8 beads/ All tissue collection was performed with local ethical approval ml. Since expression of L-NGFr is trypsin sensitive (our own including informed consent from South Glasgow University unpublished observation), hOECs trypsinized from culture Hospitals Ethics Committee. The maximum time between were incubated at 37°C for 1-5 h to allow re-expression of resection and tissue culture was usually no greater than 1 h. the L-NGFr. A total of 1 ϫ 10 6 OECs per ml were incubated In one instance, viable cells were cultured from a sample with 1 ϫ 10 7 beads, rotated at 4°C for 5 min and beadkept overnight at 4°C. However, optimal viability was found bound cells were separated using the magnet. After three with freshly dissociated tissue. Age of donor ranged from 15 washes in DMEM containing 1% FCS, cells were resuspended to 66 years and OECs were obtained from all samples in 200 µl of DMEM ϩ 1% FCS, treated with DNase (250 cultured. Tissue was cleared of blood and meninges, chopped U) and purified cells were collected and plated on coverslips into small pieces and incubated with collagenase (ICN to assess purity using the antibody to L-NGFr. Pharmaceuticals Ltd, Basingstoke, UK; 13.3 mg/ml) for 10 min at 37°C. After centrifugation and resuspension, cells
Measurement of cell proliferation
were grown in Dulbecco's modified Eagle's medium (DMEM) Cells were washed twice in serum-free modified DMEM (Gibco Life Technologies, Paisley, UK) containing 10% medium (DMEM-BS, where BS represents Bottenstein and foetal calf serum (FCS), fungazone (Gibco, 0.625 µg/ml) and Sato) (Bottenstein et al., 1979) , followed by incubation for gentamicin (Gibco, 25 µg/ml) on poly-L-lysine (Sigma, Poole, 4 days in the appropriate culture conditions. On day 3, the Dorset, UK; 13 µg/ml) coated flasks and dishes. Routine cells were incubated with 20 µM bromodeoxyuridine (BrdU, media supplements were based on optimal conditions for rat Boehringer Manneheim) overnight, followed by immunoOECs (rOECs) as described in Franceschini and Barnett labelling with the cell surface marker, anti-L-NGFr (Roche (Franceschini and Barnett, 1996) and by Pollock and Diagnostics Ltd) , and anti-BrdU on day 4 (Harlan Sera colleagues (Pollock et al., 1999) . These were human-specific Laboratories, Loughborough, UK) as previously described neuregulin heregulin (HRG) β1 (R&D Systems, Abingdon, (Pollock et al., 1999) . UK; 100 ng/ml); DMEM containing 10% FCS or conditioned medium from rat type-1 astrocytes (astrocyte conditioned medium, ACM) (Noble and Murray, 1984) . Mitogenic
Transplantation into areas of persistent
response of hOECs to PDGF (platelet-derived growth factor) AA or BB (R&D Systems), bFGF (basic fibroblast growth demyelination A focal area containing demyelinated axons was created in the factor; Peprotech EC Ltd, London, UK) and insulin-like growth factor (IGF)-I and -II (Boehringer Mannheim, dorsal funiculus of the spinal cord of adult rats using the X-irradiated ethidium bromide (X-EB) lesion model described unpurified cultures with a range of neural markers demonstrated that 66% of the cells expressed the L-NGFr. in detail by Blakemore and Crang (Blakemore and Crang, The remaining cell population included 15% VWF-expressing 1992). Two experimental groups were used. In the first group endothelial cells and 11% fibronectin-expressing fibroblasts. (n ϭ 6), cells were transplanted into female Sprague-Dawley Cells were also identified which were immunolabelled with rats (180-230 g). In the second group (n ϭ 4), cells were antibodies to GFAP (71%), S-100 (61%) and laminin (76%), transplanted into female nude rats (150-180 g). All rats were and all of the cells expressed the intermediate filament vimentin supplied by Harlan Olac Ltd, Oxon, UK. The X-EB lesion ( Fig. 1B-G ). Purer populations of OECs were obtained by model involves exposing a length of thoracolumbar spinal cord selecting those cells expressing L-NGFr using L-NGFr to 40 Gy of X-irradiation 3 days prior to injecting, via a dorsal antibody coupled to magnetic beads. Immunolabelling of these laminectomy, 1 µl of 0.1% ethidium bromide (EB) directly into purified cultures with a range of OEC markers demonstrated the dorsal funiculus in the middle of the irradiated zone using that an enrichment of the primary culture of up to 25-fold could a glass micropipette attached to a 10 µl Hamilton syringe. This be achieved depending on the proportion of L-NGFr in the procedure creates a fusiform area of demyelination of between starting population of cells. 4 and 7 mm in length and occupying Ͼ60% of the transverse width of the dorsal funiculus at its widest point. The lesioned area contains demyelinated axons, but is entirely devoid of Growth factor requirements of hOECs glial cells. There is now substantial evidence that the X-EB We next identified tissue culture conditions that induced lesion is not repaired by host-derived glial cells and a glial proliferation of the sorted L-NGFr-expressing OECs. The environment can only be reconstituted around the demyelinated hOEC has similar tissue culture requirements to rOECs, axons by glial cell transplantation (Blakemore and Crang, responding to both defined medium lacking serum conditioned 1992; Crang et al., 1992) . The advantage of this model is that by cortical astrocytes (ACM) (Noble and Murray, 1984) and glial cells identified within the lesion after transplantation can DMEM containing 10% FCS ( Fig. 2A) . We have shown be identified unequivocally as being of transplant origin previously using rOECs that the factor in ACM required for without the need to label the transplanted cells. Three days proliferation is a neuregulin isoform (Pollock et al., 1999) . We after lesion induction, a suspension of 5 ϫ 10 4 purified hOECs therefore tested HRG β1 for its capacity to induce hOEC in MEM (minimal essential medium) buffered with HEPES proliferation and found that 100 ng/ml HRG β1 caused a was injected into the dorsal funiculus at the same point at 2-fold increase in the number of BrdUϩ/L-NGFrϩ cells which the EB had been injected. Sprague-Dawley rats were compared with culturing in defined serum-free medium alone immunosuppressed by daily subcutaneous injection of (DMEM-BS) (Bottenstein et al., 1979) . Addition of 2 ϫ 15 mg/kg of cyclosporin A (Novartis Pharmaceuticals UK Ltd, 10 -6 M forskolin and 100 ng/ml HRG β1 resulted in a Surrey, UK). Rats were perfused via the descending aorta with 2.3-fold increase (Figs 2B and 3). The increase in proliferation 4% glutaraldehyde under deep pentobarbitone anaesthesia, and was statistically significant for the HRG β1-and forskolinthe fixed tissue was processed into resin from which sections treated cells (P ϭ 0.087) but less so for the ACM-treated (P ϭ were cut for light and electron microscopy. Selected resin 0.48) and HRG β1-treated (P ϭ 0.29) cells. This correlates sections were immunostained for the presence of P0, a with data obtained for human and rat Schwann cells, where peripheral myelin-specific glycoprotein. To do this, the sections neuregulin is a mitogen for these cells in both species (Casella were etched by a series of washes in a 1 : 1 sodium ethoxide / et al., 1996) . However, like human adult Schwann cells, this ethanol solution, 3% hydrogen peroxide in methanol and 8% growth factor requirement could not maintain the cells in formic acid. The sections were pre-blocked with normal culture for more than five passages. In addition, it was only goat serum before incubation with the primary antibody mitogenic for a proportion of hOECs, and prolonged exposure (1 : 500 polyclonal rabbit anti-P0, a gift from Professor Ian to heregulin β1 did not result in continued proliferation, Griffiths). The primary antibody was visualized using indicating that other factors are required for maintenance of biotinylated goat anti-rabbit antibodies and the 'Vectastain proliferation of hOECs. PDGF AA or BB, bFGF, NGF, IGF-I elite' diaminobenzidine system (Vector Laboratories, or GGF (glial growth factor) were not mitogenic for hOECs Peterborough, UK).
(data not shown). When cells purified to Ͼ68% L-NGFr positive were placed in DMEM containing 10% FCS for 4 days, only 15% of the hOECs (still identifiable as such on the basis of S-100 and GFAP immunoreactivity) expressed L-
Results
NGFr. Thus, L-NGFr expression by hOECs is lost rapidly in
Characterization of cells isolated from human
these conditions.
olfactory bulbs
Cells from human olfactory bulb were cultured using a method hOECs remyelinate demyelinated CNS axons previously developed for culturing rodent OECs with which it was possible to establish cultures of extremely high viability following transplantation (Barnett et al., 1993) . Cultured cells were obtained from all of Since transplantation of OECs has been proposed as a cellular therapy for both demyelination and axonal injury in the seven samples taken (Fig. 1A) . Initial immunolabelling of these CNS, we examined whether hOECs were capable of L-NGFr positive was injected into Sprague-Dawley rats, immunosuppressed by daily injection of cyclosporin to remyelinating persistently demyelinated CNS axons by transplanting L-NGFr-purified hOECs into experimentally prevent rejection of the transplanted cells. The remaining non-L-NGFr-positive cells comprise the astrocyte-like OECs induced demyelinating lesions. These lesions were created using a standard model which involved creating focal areas (Franceschini and Barnett, 1996) , OECs that had lost L-NGFr and some endothelial cells, fibroblasts and meningeal of demyelination in the dorsal funiculus of the adult rat spinal cord by direct injection of a small volume of 0.1% cells. Three weeks after transplantation, hOECs were observed within the lesion associating with the demyelinating EB (Blakemore and Crang, 1992) . This procedure kills both astrocytes and oligodendrocytes in a clearly defined area, axons, but only on rare occasions were thin myelin sheaths identified. In a second experiment, a suspension containing while leaving the axons largely intact and demyelinated. If EB injections are made into white matter that previously has 45% L-NGFr-positive hOECs was transplanted into T-celldeficient athymic rats (used in preference to cyclosporinbeen exposed to 40 Gy of X-irradiation, then the lesion is not repopulated by host-derived glia, and the demyelinated immunosuppressed Sprague-Dawley rats, for which daily subcutaneous injections for survival periods longer than axons can only be remyelinated by transplanted cells (Fig.  4A ). This feature of the lesion has been verified by injecting 3 weeks was not deemed acceptable) and the animals analysed after a survival period of 6 weeks. In three of the four saline alone or inducing rejection of transplanted nonhistocompatible cells by removal of an immunosuprressive animals killed at 6 weeks, there was evidence of more widespread remyelination of the demyelinated axons than at regimen. In both situations, the lesions remain demyelinated (Crang and Blakemore, 1991; Crang et al., 1992) . In an 3 weeks, at which time point there is extensive remyelination by rOECs (unpublished data). The extent of remyelination initial experiment, a suspension of cells which were 30% lesions, was the presence of numerous intermediate filamentcontaining cells that formed a loose network throughout much of the lesion area ( Fig. 4F and G) . The areas in which these cells were found frequently were rich in large diameter collagen and the axons generally remained demyelinated. The presence of these cells within the lesion identified them 
Immunocytochemical profile of hOECs
To be useful in transplantation therapies, it will be necessary to grow relatively large numbers of pure hOECs and therefore was less than was achieved using either primary rOECs (unpublished observations; Imaizumi et al., 1998) or a rodent purification procedures and the ability to identify these cells are very important. rOECs have been characterized by their OEC line (Franklin et al., 1996) , and myelin sheaths were only observed in the centre of the lesion. The myelin sheaths expression of O4, anti-GFAP, anti-L-NGFr and anti-polysialic acid (a specific epitope on the embryonic form of neural cell were typical of those obtained following transplantation of rOECs, and were similarly indistinguishable from Schwann adhesion molecule E-NCAM) (Franceschini and Barnett, 1996) and have been termed astrocyte-like and Schwann cell remyelination both ultrastructurally and in the expression of the peripheral myelin-specific protein P0 (Franklin et al., cell-like according to their morphology and their antigenic phenotype (Pixley, 1992; Barnett et al., 1993) . In serum-free 1996) (Fig. 4B-E) . Also similarly to the rOEC transplants, but different from Schwann cell transplants into similar media, the hOECs expressed a heterogeneous morphology which became more uniform with a predominantly flattened rapidly lost, then selection based on its use must be carried out soon after cultures are prepared from olfactory bulb tissue. fibroblast-like morphology when cultured in DMEM-FCS. This property has been seen for rOECs . The O4 antibody did not label the hOEC to the same extent as has been shown for rOECs, and cannot
Growth factor requirements for hOECs
The growth factor requirements for hOECs were similar to therefore be used to purify the cells. Although we were not able to detect E-NCAM-positive cells in these cultures, the those of rOECs in that ACM and DMEM-FCS were mitogenic. hOECs respond to DMEM-FCS but lose L-NGFr antibodies to L-NGFr and GFAP can be used to define hOECs. hOECs can be selected for specifically using anti-Lrapidly, making continual analysis difficult. To characterize this property in detail, it would be necessary to carry out NGFr antibodies. However, since expression of this receptor is clonal analysis of the hOEC. Since this was not the primary of the transplant suspension determines the phenotypes assumed by the transplanted cells is an important issue that aim of this study, we have not addressed this point. Expression of the L-NGFr could be maintained longer for hOECs in remains to be resolved. For example, in the context of repairing an area of demyelination, the myelinating phenotype ACM or medium containing HRG β1, but these cells stopped proliferating. We have found a similar cessation of growth is clearly more desirable than a non-myelinating phenotype.
In which case, in order to optimize the extent of remyelination, for rOECs after 2-3 weeks in ACM or neuregulins (data not shown) that can be overcome by the addition of DMEMit may be necessary to select for OEC phenotypes that give rise to the remyelinating cell rather than the alternative FCS. It is clear that the growth factor requirements of hOECs are more complicated than those described for human phenotypes, prior to transplantation. The cells used in this study were obtained from adults using Schwann cells. This observation is supportive of the growing body of evidence gleaned from rodent OECs that identify invasive neurosurgical procedures. However, the olfactory epithelium and nerve located outside the cranium, in which OECs as distinct from other glial cells types of the peripheral and central nervous systems.
glial cells have been identified, may provide an alternative source of OECs. Moreover, this area can be biopsied in humans with no adverse effect (Lanza et al., 1994; Feron et al., 1998) . This would be especially true if unilateral
Transplanted hOECs differentiate into a biopsies were undertaken, which may at worst induce a myelinating phenotype in the presence of hemianosmia, a mild debility when set against the possibility demyelinated axons and behave in a manner of ameliorating the profound neurological dysfunction associated with the target diseases for transplantation therapy.
similar to that of rOECs
The encouraging data on the CNS repair potential of A more intriguing possibility however, is that OECs capable of remyelination following transplantation can be obtained transplanted OECs that have been generated thus far have involved the use of rodent cells grafted into rodent models from embryonic stem cells, the feasibility of which has been demonstrated recently for oligodendrocyte lineage cells (Franklin et al., 1996; Li et al., 1997; Imaizumi et al., 1998; Ramon-Cueto et al., 1998) . A critical question in assessing (Thomson et al., 1998; Brustle et al., 1999) . Regardless of their source, human OECs can be regarded as a feasible the clinical relevance of this work is whether the rodent OEC bears any resemblance to the human OEC. In this study, we candidate cell in formulating transplantation-based clinical trials for the treatment of traumatic and demyelinating show that OECs derived from the human olfactory system behave in a similar fashion to the rodent cell. This has diseases of the CNS. In this study, we have taken the promising data on the achieved two objectives. First, the ability of transplanted hOECs to differentiate into a myelinating phenotype that therapeutic potential of the OEC a step closer to clinical application, by identifying and characterizing the hOEC and remyelinates demyelinated axons means that one can be sanguine about the feasibility of OEC grafts to repair demonstrating that it exhibits many of the properties of the rodent OEC. In particular, we have shown that hOECs will demyelinated foci in the human CNS disease. Secondly, the similarity in the behaviour of OECs derived from human and form new myelin sheaths around demyelinated axons. These are encouraging results in the context of using OECs for rodent nervous systems validates the relevance of studies using rat cells for human disorders. cellular therapy of CNS disease in humans. It is clear from our results that not all transplanted cells adopted a myelinating phenotype since in some areas cells that did not engage in remyelination were also observed. The
